At the genomic level, p53, p21, and NPM1 are highly expressed in most tumors including thyroid cancer, whereas PAD4 levels are low, except in acute myeloid leukemia and thymoma (Figure S7). This evidence concerns the gene CDKN1A and thyroid gland carcinoma.